EA201490840A1 - Препарат с замедленным высвобождением - Google Patents

Препарат с замедленным высвобождением

Info

Publication number
EA201490840A1
EA201490840A1 EA201490840A EA201490840A EA201490840A1 EA 201490840 A1 EA201490840 A1 EA 201490840A1 EA 201490840 A EA201490840 A EA 201490840A EA 201490840 A EA201490840 A EA 201490840A EA 201490840 A1 EA201490840 A1 EA 201490840A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pioglitazone
slowed
delivery
preparation
salt
Prior art date
Application number
EA201490840A
Other languages
English (en)
Russian (ru)
Inventor
Ютака Таноуе
Юсуке Муракава
Юмико Исии
Каору Такенака
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490840(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201490840A1 publication Critical patent/EA201490840A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201490840A 2011-10-21 2012-10-19 Препарат с замедленным высвобождением EA201490840A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
EA201490840A1 true EA201490840A1 (ru) 2014-08-29

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490840A EA201490840A1 (ru) 2011-10-21 2012-10-19 Препарат с замедленным высвобождением

Country Status (30)

Country Link
US (1) US9907789B2 (enExample)
EP (1) EP2768487B1 (enExample)
JP (1) JP6093762B2 (enExample)
KR (1) KR20140081826A (enExample)
CN (1) CN104039313A (enExample)
AP (1) AP2014007645A0 (enExample)
AR (1) AR088398A1 (enExample)
AU (1) AU2012326976B2 (enExample)
BR (1) BR112014008744A2 (enExample)
CA (1) CA2852417A1 (enExample)
CL (1) CL2014000992A1 (enExample)
CO (1) CO6960544A2 (enExample)
CR (1) CR20140213A (enExample)
DO (1) DOP2014000077A (enExample)
EA (1) EA201490840A1 (enExample)
EC (1) ECSP14013328A (enExample)
IL (1) IL232114A0 (enExample)
IN (1) IN2014DN03169A (enExample)
MA (1) MA35717B1 (enExample)
MX (1) MX2014004679A (enExample)
NZ (1) NZ624275A (enExample)
PE (1) PE20141189A1 (enExample)
PH (1) PH12014500856A1 (enExample)
SG (2) SG2014012025A (enExample)
TN (1) TN2014000152A1 (enExample)
TW (1) TW201323018A (enExample)
UA (1) UA113858C2 (enExample)
UY (1) UY34403A (enExample)
WO (1) WO2013058409A1 (enExample)
ZA (1) ZA201403103B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
ES2668422T3 (es) 2012-04-20 2018-05-18 Gilead Sciences, Inc. Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE69332081T2 (de) 1992-09-18 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelzubereitung mit verzögerter freisetzung
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2003013609A1 (fr) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
IN192749B (enExample) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
EP1607088B1 (en) 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
WO2004108161A1 (ja) 2003-06-06 2004-12-16 Takeda Pharmaceutical Company Limited 固形製剤
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
EP1789022A2 (en) 2004-08-31 2007-05-30 Pfizer Products Incorporated Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
KR20080058413A (ko) 2005-09-22 2008-06-25 에스비 팜코 푸에르토 리코 인크. Apoe4 음성 환자에서의 인지 기능의 개선을 위한ppar-감마 작동제
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
KR20080080126A (ko) 2005-12-22 2008-09-02 다케다 야쿠힌 고교 가부시키가이샤 인슐린 감작제를 함유하는 고체 제제
PL2002828T3 (pl) 2006-03-30 2019-11-29 Nippon Zoki Pharmaceutical Co Stały preparat farmaceutyczny
PE20080696A1 (es) 2006-04-27 2008-08-04 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y clorhidrato de pioglitazona
AU2008213744B2 (en) 2007-02-09 2013-12-05 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
AU2009298684B2 (en) 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
PH12013501450A1 (en) 2011-01-10 2013-08-28 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer`s diseases
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
EP2768487B1 (en) 2020-06-03
US9907789B2 (en) 2018-03-06
TN2014000152A1 (en) 2015-09-30
ZA201403103B (en) 2015-08-26
IL232114A0 (en) 2014-06-30
CL2014000992A1 (es) 2014-09-05
EP2768487A1 (en) 2014-08-27
AU2012326976B2 (en) 2017-08-17
AP2014007645A0 (en) 2014-05-31
KR20140081826A (ko) 2014-07-01
BR112014008744A2 (pt) 2017-04-18
AU2012326976A1 (en) 2014-05-29
NZ624275A (en) 2016-09-30
AU2012326976A2 (en) 2014-06-12
AR088398A1 (es) 2014-05-28
PH12014500856A1 (en) 2014-05-19
DOP2014000077A (es) 2014-07-15
JP6093762B2 (ja) 2017-03-08
JP2014530802A (ja) 2014-11-20
PE20141189A1 (es) 2014-09-24
SG2014012025A (en) 2014-06-27
CR20140213A (es) 2014-06-18
UA113858C2 (uk) 2017-03-27
ECSP14013328A (es) 2014-05-31
WO2013058409A1 (en) 2013-04-25
SG10201700121YA (en) 2017-03-30
MA35717B1 (fr) 2014-12-01
UY34403A (es) 2013-05-31
CA2852417A1 (en) 2013-04-25
CO6960544A2 (es) 2014-05-30
MX2014004679A (es) 2014-08-01
CN104039313A (zh) 2014-09-10
US20140248362A1 (en) 2014-09-04
IN2014DN03169A (enExample) 2015-05-22
TW201323018A (zh) 2013-06-16

Similar Documents

Publication Publication Date Title
EA201490840A1 (ru) Препарат с замедленным высвобождением
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
EA201300989A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
EA201492292A1 (ru) Препарат антител
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
NZ602685A (en) Concentrated protein formulations and uses thereof
MX389052B (es) Formulaciones de insulina de accion prolongada.
MX378502B (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
IN2014MN01470A (enExample)
IN2014MN02213A (enExample)
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
EA201391018A1 (ru) Препараты иммуносупрессантов
ZA201508924B (en) Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
JO3683B1 (ar) صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها
JP2016503058A5 (enExample)
BR112015028824A2 (pt) composição de tensoativo concentrada
EA201892563A1 (ru) Композиция для местного применения
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
AR080127A1 (es) Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos
EA201401200A1 (ru) Новая композиция альфентанила для лечения острой боли
TR201815617A2 (tr) Deksketoprofen içeren bir formülasyon.